ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider Sells $114,393.18 in Stock

Posted by Francis Steltz on May 30th, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) insider James Kihara sold 5,401 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

James Kihara also recently made the following trade(s):

On Monday, May 4th, James Kihara sold 1,332 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $21.79, for a total value of $29,024.28.
On Tuesday, April 7th, James Kihara sold 1,030 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $22.20, for a total value of $22,866.00.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $21.66 on Friday. The business has a 50 day simple moving average of $21.74 and a 200 day simple moving average of $23.81. ACADIA Pharmaceuticals Inc. has a 52-week low of $19.69 and a 52-week high of $28.35. The stock has a market cap of $3.71 billion, a price-to-earnings ratio of 9.85, a PEG ratio of 26.19 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The business had revenue of $268.10 million for the quarter, compared to the consensus estimate of $280.25 million. During the same period in the previous year, the company posted $0.11 earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.39 EPS for the current year.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of large investors have recently bought and sold shares of ACAD. Royal Bank of Canada boosted its position in ACADIA Pharmaceuticals by 74.4% during the 1st quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock worth $1,338,000 after acquiring an additional 34,352 shares during the last quarter. AQR Capital Management LLC boosted its position in ACADIA Pharmaceuticals by 3.8% during the 1st quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock worth $1,124,000 after acquiring an additional 2,492 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in ACADIA Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock worth $1,498,000 after acquiring an additional 6,303 shares during the last quarter. Empowered Funds LLC acquired a new position in ACADIA Pharmaceuticals during the 1st quarter worth approximately $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in ACADIA Pharmaceuticals by 14.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock worth $4,170,000 after acquiring an additional 31,931 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

ACAD has been the subject of a number of research reports. Mizuho raised ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $29.00 to $35.00 in a research note on Monday, February 23rd. Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Stifel Nicolaus lowered their target price on ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. Wolfe Research initiated coverage on ACADIA Pharmaceuticals in a research note on Monday, February 23rd. They set an “outperform” rating and a $33.00 target price for the company. Finally, Citizens Jmp increased their target price on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $31.63.

Check Out Our Latest Analysis on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Profile

(Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.